MarketPeel
Insider Trading Intelligence
Pricing
…
FU

Forbion Growth Opportunities Fund I. Cooperatief U.a.

NAMS
10% OWNER · NEWAMSTERDAM PHARMA CO N.V. · CIK 0001911047
FILING MIX · LIFETIME42%/58%
BUYS
18
SELLS
25
TOTAL VALUE
$38.03M
COMPANIES
2
ACTIVE SINCE
Oct 2023
HOLDINGS NOW
13,688,602
AVG SELL PX
$25.54
TRADE KIND
SHOWING 43 / 43
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
39 backtested trades · 8 horizons · 35 pending
Forward-return performance of every backtestable P/S trade by Forbion Growth Opportunities Fund I. Cooperatief U.a., measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d39+51.28%+0.21%-0.25%+0.46%+1.36%0.29
14d39+58.97%+4.63%+0.26%+4.37%+1.59%1.71
30d39+84.62%+3.79%+0.47%+3.32%-0.81%1.14
60d39+97.44%+2.26%+2.63%-0.37%-22.91%-0.07
90d39+97.44%+4.06%-0.68%+4.74%-2.34%0.88
180d39+66.67%-24.13%+1.26%-25.39%-26.15%-21.03
1y39+23.08%+25.56%+16.66%+8.89%+19.32%2.04
2y39(35 pending)+50.00%+10.61%+47.08%-36.46%-39.52%—
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
NAMS · 10,656,172 shares · as of Dec 30, 2024
02,957,5995,915,1988,872,79611,830,395SHARES HELD
Trading cadence · quarterly flow
BUY ● SELL ●
2023
2024
2024
2024
2024
FLOW · 18 buys / 25 sellsCOVERAGE · 5 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
NAMS
NEWAMSTERDAM PHARMA CO N.V.
SALE10b5-1
10b5-1 plan
29,846$25.54$762.2K10,656,172Dec 30, 2024Jan 2, 2025 ↗View →
NAMS
NEWAMSTERDAM PHARMA CO N.V.
SALE10b5-1
10b5-1 plan
41,472$25.95$1.08M10,686,018Dec 27, 2024Dec 30, 2024 ↗View →
NAMS
NEWAMSTERDAM PHARMA CO N.V.
SALE10b5-1
10b5-1 plan
33,438$26.01$869.6K10,727,490Dec 26, 2024Dec 30, 2024 ↗View →
NAMS
NEWAMSTERDAM PHARMA CO N.V.
SALE10b5-1
10b5-1 plan
16,164$25.66$414.8K10,760,928Dec 24, 2024Dec 26, 2024 ↗View →
NAMS
NEWAMSTERDAM PHARMA CO N.V.
SALE10b5-1
10b5-1 plan
25,132$25.49$640.6K10,777,092Dec 23, 2024Dec 26, 2024 ↗View →
NAMS
NEWAMSTERDAM PHARMA CO N.V.
SALE10b5-1
10b5-1 plan
5,629$26.13$147.1K10,802,224Dec 20, 2024Dec 26, 2024 ↗View →
NAMS
NEWAMSTERDAM PHARMA CO N.V.
SALE10b5-1
10b5-1 plan
44,143$25.53$1.13M10,807,853Dec 20, 2024Dec 26, 2024 ↗View →
NAMS
NEWAMSTERDAM PHARMA CO N.V.
SALE10b5-1
10b5-1 plan
56,506$25.45$1.44M10,851,996Dec 19, 2024Dec 20, 2024 ↗View →
NAMS
NEWAMSTERDAM PHARMA CO N.V.
SALE10b5-1
10b5-1 plan
46,210$26.55$1.23M10,908,502Dec 18, 2024Dec 20, 2024 ↗View →
NAMS
NEWAMSTERDAM PHARMA CO N.V.
SALE10b5-1
10b5-1 plan
54,518$25.72$1.40M10,954,712Dec 18, 2024Dec 20, 2024 ↗View →
NAMS
NEWAMSTERDAM PHARMA CO N.V.
SALE10b5-1
10b5-1 plan
47,736$26.45$1.26M11,009,230Dec 17, 2024Dec 18, 2024 ↗View →
NAMS
NEWAMSTERDAM PHARMA CO N.V.
SALE10b5-1
10b5-1 plan
66,648$25.60$1.71M11,056,966Dec 17, 2024Dec 18, 2024 ↗View →
NAMS
NEWAMSTERDAM PHARMA CO N.V.
SALE10b5-1
10b5-1 plan
1,096$25.00$27.4K11,123,614Dec 16, 2024Dec 18, 2024 ↗View →
NAMS
NEWAMSTERDAM PHARMA CO N.V.
SALE10b5-1
10b5-1 plan
25,751$25.01$644.0K11,124,710Dec 13, 2024Dec 16, 2024 ↗View →
NAMS
NEWAMSTERDAM PHARMA CO N.V.
SALE10b5-1
10b5-1 plan
140,048$25.25$3.54M11,176,424Dec 12, 2024Dec 16, 2024 ↗View →
NAMS
NEWAMSTERDAM PHARMA CO N.V.
SALE10b5-1
10b5-1 plan
25,963$26.18$679.6K11,150,461Dec 12, 2024Dec 16, 2024 ↗View →
NAMS
NEWAMSTERDAM PHARMA CO N.V.
SALE10b5-1
10b5-1 plan
4,894$27.11$132.7K11,316,472Dec 11, 2024Dec 12, 2024 ↗View →
NAMS
NEWAMSTERDAM PHARMA CO N.V.
SALE10b5-1
10b5-1 plan
18,583$26.41$490.7K11,321,366Dec 11, 2024Dec 12, 2024 ↗View →
NAMS
NEWAMSTERDAM PHARMA CO N.V.
SALE10b5-1
10b5-1 plan
130,561$25.26$3.30M11,339,949Dec 11, 2024Dec 12, 2024 ↗View →
NAMS
NEWAMSTERDAM PHARMA CO N.V.
SALE10b5-1
10b5-1 plan
48,511$26.15$1.27M11,470,510Dec 10, 2024Dec 12, 2024 ↗View →
NAMS
NEWAMSTERDAM PHARMA CO N.V.
SALE10b5-1
10b5-1 plan
259,739$25.22$6.55M11,519,021Dec 10, 2024Dec 12, 2024 ↗View →
NAMS
NEWAMSTERDAM PHARMA CO N.V.
SALE10b5-1
10b5-1 plan
33,273$25.08$834.4K11,778,760Nov 18, 2024Nov 19, 2024 ↗View →
NAMS
NEWAMSTERDAM PHARMA CO N.V.
SALE10b5-1
10b5-1 plan
8,530$25.02$213.4K11,812,033Nov 15, 2024Nov 19, 2024 ↗View →
NAMS
NEWAMSTERDAM PHARMA CO N.V.
SALE10b5-1
10b5-1 plan
9,832$25.01$245.9K11,820,563Nov 14, 2024Nov 15, 2024 ↗View →
NAMS
NEWAMSTERDAM PHARMA CO N.V.
SALE10b5-1
10b5-1 plan
1,066$25.00$26.7K11,830,395Nov 13, 2024Nov 15, 2024 ↗View →
ENGN
ENGENE THERAPEUTICS INC.
PURCHASE
561,797$8.90$5.00M3,032,430Oct 30, 2024Nov 1, 2024 ↗View →
ENGN
ENGENE THERAPEUTICS INC.
PURCHASE
800$6.60$5.3K2,470,633Oct 8, 2024Oct 18, 2024 ↗View →
ENGN
ENGENE THERAPEUTICS INC.
PURCHASE
11,844$6.55$77.5K2,469,833Oct 7, 2024Oct 18, 2024 ↗View →
ENGN
ENGENE THERAPEUTICS INC.
PURCHASE
5,997$6.54$39.2K2,457,989Oct 4, 2024Oct 18, 2024 ↗View →
ENGN
ENGENE THERAPEUTICS INC.
PURCHASE
5,769$6.48$37.4K2,451,992Oct 3, 2024Oct 18, 2024 ↗View →
ENGN
ENGENE THERAPEUTICS INC.
PURCHASE
10,153$6.37$64.7K2,446,223Oct 2, 2024Oct 18, 2024 ↗View →
ENGN
ENGENE THERAPEUTICS INC.
PURCHASE
35,279$6.44$227.2K2,436,070Oct 1, 2024Oct 18, 2024 ↗View →
ENGN
ENGENE THERAPEUTICS INC.
PURCHASE
341,332$6.34$2.16M2,400,791Sep 30, 2024Oct 18, 2024 ↗View →
ENGN
ENGENE THERAPEUTICS INC.
PURCHASE
3,243$6.38$20.7K2,059,459Sep 27, 2024Oct 18, 2024 ↗View →
ENGN
ENGENE THERAPEUTICS INC.
PURCHASE
38,396$5.94$228.0K2,056,216Sep 27, 2024Oct 18, 2024 ↗View →
ENGN
ENGENE THERAPEUTICS INC.
PURCHASE
9,620$9.09$87.5K2,017,820Dec 29, 2023Oct 18, 2024 ↗View →
ENGN
ENGENE THERAPEUTICS INC.
PURCHASE
400$8.30$3.3K2,008,200Dec 29, 2023Oct 18, 2024 ↗View →
ENGN
ENGENE THERAPEUTICS INC.
PURCHASE
5,050$7.69$38.8K2,007,800Dec 28, 2023Oct 18, 2024 ↗View →
ENGN
ENGENE THERAPEUTICS INC.
PURCHASE
2,750$7.17$19.7K2,002,750Dec 27, 2023Oct 18, 2024 ↗View →
ENGN
ENGENE THERAPEUTICS INC.
PURCHASE
2,262,351——3,765,932Oct 31, 2023Nov 2, 2023 ↗View →
ENGN
ENGENE THERAPEUTICS INC.
PURCHASE
950,153——1,736,406Oct 31, 2023Nov 2, 2023 ↗View →
ENGN
ENGENE THERAPEUTICS INC.
PURCHASE
130,085——1,503,581Oct 31, 2023Nov 2, 2023 ↗View →
ENGN
ENGENE THERAPEUTICS INC.
PURCHASE
54,634——786,253Oct 31, 2023Nov 2, 2023 ↗View →
Other insiders · NAMS
Loading peer insiders…
About this filer
CIK 0001911047
ROLE
10% Owner
PRIMARY
NAMS
COMPANIES
2
ACTIVE SINCE
Oct 2023
MARKETPEEL · /INSIDER/0001911047DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

The morning brief, before the bell.

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback